SK Biopharmaceuticals326030.KS
本公司簡介的中文翻譯準備中。以下為英文原文。
關於SK Biopharmaceuticals
SK Biopharmaceuticals discovers and develops central-nervous-system drugs, and stands out among Korean pharmaceutical companies for selling its lead product in the United States through its own commercial organization rather than a licensing partner. That product, the epilepsy treatment cenobamate, marketed as XCOPRI in the U.S., anchors revenue, supplemented by licensing income from partners that sell its compounds in other regions. The company is a subsidiary of SK Inc., the holding company of SK Group, and is working to extend its pipeline into additional neurological and oncology targets over time.
Concentration is the defining structural issue: earnings rest heavily on a single epilepsy franchise in a single market, so U.S. prescription trends, payer dynamics, and eventual patent life dominate the investment case. The direct-sales model gives the company full product economics but also full fixed costs, an unusual profile among Korean biotechs. Majority ownership by SK Inc. constrains free float and keeps strategy aligned with group priorities. Investors also track how licensing arrangements in Europe, Asia, and elsewhere convert the lead molecule into royalty streams.
SK Group's pharmaceutical ambitions date to 1993, when the group opened a drug-discovery research program, unusually early for a Korean conglomerate. That effort was reorganized in 2011 into SK Biopharmaceuticals, a dedicated subsidiary held directly by the group holding company, with a U.S. commercial affiliate, SK Life Science, later established in New Jersey. Decades of internal research culminated in the U.S. approval of the epilepsy drug cenobamate in 2019, a molecule discovered and developed wholly in-house. The company went public on the KOSPI in July 2020 in one of the most heavily subscribed Korean listings on record.
Commercial machinery matters as much as science here. In the United States, SK Life Science's sales force calls on neurologists and epilepsy centers, and revenue builds as physicians step patients onto cenobamate and insurers grant formulary access, a gradual accumulation typical of antiseizure launches. Elsewhere the company converts its molecule into partnership income: Angelini Pharma markets the drug in Europe under the Ontozry name, and regional licensees cover other territories, paying milestones as approvals arrive. Manufacturing is largely outsourced, keeping the company asset-light. Pipeline programs in neurology and oncology aim to reduce single-product dependence over time.
公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫SK Biopharmaceuticals的DART完整報告 →
SK Biopharmaceuticals相關報導
2篇文章
SK Biopharmaceuticals Signs USD 2.5 Billion AI Drug Discovery Deal With Insilico Medicine at BioUSA 2026, Expanding CNS Reach Beyond Epilepsy
SK Biopharmaceuticals (326030.KS) signed a USD 2.5 billion AI drug discovery deal with Insilico Medicine at BioUSA 2026 to develop neuroimmune CNS therapies, as 51 Korean biotech firms set new partnership benchmarks at the San Diego event.
付費專屬SK Biopharma (326030.KS) Q1 2026: Cenobamate Lifts Operating Profit 250%, Margin Hits 39%
Single-drug operating leverage transforms SK Biopharmaceuticals from loss-making drug launcher to high-margin cash generator — operating margin more than doubles year-over-year.
常見問題
What does SK Biopharmaceuticals do?
SK Biopharmaceuticals discovers and develops medicines for central-nervous-system disorders. Its flagship product is cenobamate, an antiseizure treatment sold as XCOPRI in the United States through its own subsidiary and licensed to partners elsewhere. The company also researches additional neurology and oncology candidates from laboratories in South Korea and the United States.
Who controls SK Biopharmaceuticals?
SK Inc., the holding company at the top of SK Group, owns a majority of SK Biopharmaceuticals and consolidates it as a subsidiary. Group leadership rests with Chairman Chey Tae-won and the Chey family, who guide SK Inc. The majority stake leaves a comparatively small free float trading on the market.
How can foreign investors get exposure to SK Biopharmaceuticals?
The stock trades on the Korea Exchange's KOSPI market under ticker 326030. Foreign investors can purchase shares through brokers offering Korean market access once registered with local authorities, or gain indirect exposure through Korea equity funds and health-care-themed vehicles that include the company. It does not have a U.S. listing.
答覆為一般資訊之編輯摘要，非投資建議。
深入標題背後
您剛讀到發生了什麼。接下來，讀懂它意味著什麼。
每天早晨的韓國市場 — 免費
LineVest Daily在首爾開盤前送達您的信箱：KOSPI與KOSDAQ關鍵報導、財報、披露與外資流向 — 以簡明英文呈現。免費，無需信用卡。
SK Biopharmaceuticals完整報告
我們完整閱讀SK Biopharmaceuticals的最新DART披露 — K-IFRS財務、公司治理，以及對股價的意義。3小時內PDF送達您的信箱。
$12 · 單次
獲取SK Biopharmaceuticals報告基於DART原始披露的獨立新聞報導 — 非投資建議。與任何券商無關。